Benitec Biopharma

$2.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-11.00%) As of 6:59 PM UTC today

Why Robinhood?

You can buy or sell BNTC and other stocks, options, and ETFs commission-free!

About BNTC

Benitec Biopharma Inc. Common Stock, also called Benitec Biopharma, is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA. The listed name for BNTC is Benitec Biopharma Inc. Common Stock.

CEO

Jerel A. Banks

Employees

—

Headquarters

Hayward, California

Founded

2020

Market Cap

11.81M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

546.07K

High Today

$3.02

Low Today

$2.54

Open Price

$2.93

Volume

353.41K

52 Week High

$17.39

52 Week Low

$2.52

BNTC Earnings

-$2.45

-$1.63

-$0.82

$0.00

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Q2 FY21

Q3 FY21

Estimated

— per share

Actual

Expected Jun 22, Pre-Market